AdultPediatricDosage Forms & Strengths transdermal patch: Schedule II Daytrana 10mg/9hr 15mg/9hr 20mg/9hr 30mg/9hr Attention Deficit Hyperactivity Disorder Indicated for attention deficit hyperactivity disorder (ADHD) Starting dose for patients new to or converting from another formulation of methylphenidate is 10 mg Apply patch on hip 2 hr before desired onset; remove after 9 hr; alternate application site Individualize dose titration, final dosage, and wear time according to patient needs and response Titrate to effect for best results Week 1: 10 mg (12.5-cm2 patch); releases 1.1 mg/hr Week 2: 15 mg (18.75-cm2 patch); releases 1.6 mg/hr Week 3: 20 mg (25-cm2 patch); releases 2.2 mg/hr Week 4: 30 mg (37.5-cm2 patch); releases 3.3 mg/hr Dosage Forms & Strengths transdermal patch: Schedule II Daytrana 10mg/9hr 15mg/9hr 20mg/9hr 30mg/9hr Attention Deficit Hyperactivity Disorder Indicated for attention deficit hyperactivity disorder (ADHD) in patients aged >6 years <6 years: Safety and efficacy not established ≥6 years Starting dose for patients new to or converting from another formulation of methylphenidate is 10 mg Apply patch on hip 2 hr before desired onset; remove after 9 hr; alternate application site Individualize dose titration, final dosage, and wear time according to patient needs and response Titrate to effect for best results Week 1: 10 mg (12.5-cm2 patch); releases 1.1 mg/hr Week 2: 15 mg (18.75-cm2 patch); releases 1.6 mg/hr Week 3: 20 mg (25-cm2 patch); releases 2.2 mg/hr Week 4: 30 mg (37.5-cm2 patch); releases 3.3 mg/hr Interaction CheckerEnter a drug name and methylphenidate transdermalNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (7)isocarboxazidmethylphenidate transdermal and isocarboxazid both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.phenelzinemethylphenidate transdermal and phenelzine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.rasagilinemethylphenidate transdermal and rasagiline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.safinamidemethylphenidate transdermal and safinamide both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.selegilinemethylphenidate transdermal and selegiline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.selegiline transdermalmethylphenidate transdermal and selegiline transdermal both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.tranylcyprominemethylphenidate transdermal and tranylcypromine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.Serious - Use Alternative (0)Monitor Closely (91)acebutololmethylphenidate transdermal decreases effects of acebutolol by anti-hypertensive channel blocking. Use Caution/Monitor.acetazolamidemethylphenidate transdermal will increase the level or effect of acetazolamide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. amiloridemethylphenidate transdermal decreases effects of amiloride by anti-hypertensive channel blocking. Use Caution/Monitor.amitriptylinemethylphenidate transdermal will increase the level or effect of amitriptyline by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. amoxapinemethylphenidate transdermal will increase the level or effect of amoxapine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. azilsartanmethylphenidate transdermal decreases effects of azilsartan by anti-hypertensive channel blocking. Use Caution/Monitor.benazeprilmethylphenidate transdermal decreases effects of benazepril by anti-hypertensive channel blocking. Use Caution/Monitor.candesartanmethylphenidate transdermal decreases effects of candesartan by anti-hypertensive channel blocking. Use Caution/Monitor.cannabidiolmethylphenidate transdermal will increase the level or effect of cannabidiol by anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. captoprilmethylphenidate transdermal decreases effects of captopril by anti-hypertensive channel blocking. Use Caution/Monitor.carbamazepinemethylphenidate transdermal will increase the level or effect of carbamazepine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. cenobamatemethylphenidate transdermal will increase the level or effect of cenobamate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. chlorothiazidemethylphenidate transdermal decreases effects of chlorothiazide by anti-hypertensive channel blocking. Use Caution/Monitor.chlorthalidonemethylphenidate transdermal decreases effects of chlorthalidone by anti-hypertensive channel blocking. Use Caution/Monitor.citaloprammethylphenidate transdermal will increase the level or effect of citalopram by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. clobazammethylphenidate transdermal will increase the level or effect of clobazam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. clomipraminemethylphenidate transdermal will increase the level or effect of clomipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. clonazepammethylphenidate transdermal will increase the level or effect of clonazepam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. clorazepatemethylphenidate transdermal will increase the level or effect of clorazepate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. conivaptanmethylphenidate transdermal and conivaptan both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.desipraminemethylphenidate transdermal will increase the level or effect of desipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. desmopressinmethylphenidate transdermal and desmopressin both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.diazepammethylphenidate transdermal will increase the level or effect of diazepam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. diazepam buccalmethylphenidate transdermal will increase the level or effect of diazepam buccal by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. diazepam intranasalmethylphenidate transdermal will increase the level or effect of diazepam intranasal by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. divalproex sodiummethylphenidate transdermal will increase the level or effect of divalproex sodium by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. doxepinmethylphenidate transdermal will increase the level or effect of doxepin by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. enalaprilmethylphenidate transdermal decreases effects of enalapril by anti-hypertensive channel blocking. Use Caution/Monitor.eprosartanmethylphenidate transdermal decreases effects of eprosartan by anti-hypertensive channel blocking. Use Caution/Monitor.escitaloprammethylphenidate transdermal will increase the level or effect of escitalopram by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. eslicarbazepine acetatemethylphenidate transdermal will increase the level or effect of eslicarbazepine acetate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. esmololmethylphenidate transdermal decreases effects of esmolol by anti-hypertensive channel blocking. Use Caution/Monitor.ethosuximidemethylphenidate transdermal will increase the level or effect of ethosuximide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. ethotoinmethylphenidate transdermal will increase the level or effect of ethotoin by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. ezogabinemethylphenidate transdermal will increase the level or effect of ezogabine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. felbamatemethylphenidate transdermal will increase the level or effect of felbamate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. fenfluraminemethylphenidate transdermal will increase the level or effect of fenfluramine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. fluoxetinemethylphenidate transdermal will increase the level or effect of fluoxetine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. fluvoxaminemethylphenidate transdermal will increase the level or effect of fluvoxamine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. fosinoprilmethylphenidate transdermal decreases effects of fosinopril by anti-hypertensive channel blocking. Use Caution/Monitor.fosphenytoinmethylphenidate transdermal will increase the level or effect of fosphenytoin by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. hydrochlorothiazidemethylphenidate transdermal decreases effects of hydrochlorothiazide by anti-hypertensive channel blocking. Use Caution/Monitor.imipraminemethylphenidate transdermal will increase the level or effect of imipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. indapamidemethylphenidate transdermal decreases effects of indapamide by anti-hypertensive channel blocking. Use Caution/Monitor.irbesartanmethylphenidate transdermal decreases effects of irbesartan by anti-hypertensive channel blocking. Use Caution/Monitor.lacosamidemethylphenidate transdermal will increase the level or effect of lacosamide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. lamotriginemethylphenidate transdermal will increase the level or effect of lamotrigine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. lisinoprilmethylphenidate transdermal decreases effects of lisinopril by anti-hypertensive channel blocking. Use Caution/Monitor.lorazepammethylphenidate transdermal will increase the level or effect of lorazepam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. losartanmethylphenidate transdermal decreases effects of losartan by anti-hypertensive channel blocking. Use Caution/Monitor.methsuximidemethylphenidate transdermal will increase the level or effect of methsuximide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. methyclothiazidemethylphenidate transdermal decreases effects of methyclothiazide by anti-hypertensive channel blocking. Use Caution/Monitor.metolazonemethylphenidate transdermal decreases effects of metolazone by anti-hypertensive channel blocking. Use Caution/Monitor.midazolammethylphenidate transdermal will increase the level or effect of midazolam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. midazolam intranasalmethylphenidate transdermal will increase the level or effect of midazolam intranasal by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. moexiprilmethylphenidate transdermal decreases effects of moexipril by anti-hypertensive channel blocking. Use Caution/Monitor.nortriptylinemethylphenidate transdermal will increase the level or effect of nortriptyline by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. olmesartanmethylphenidate transdermal decreases effects of olmesartan by anti-hypertensive channel blocking. Use Caution/Monitor.oxcarbazepinemethylphenidate transdermal will increase the level or effect of oxcarbazepine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when